GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Earnings Yield (Joel Greenblatt) %

Biosyent (TSXV:RX) Earnings Yield (Joel Greenblatt) %

: 10.33% (As of Dec. 2023)
View and export this data going back to 1979. Start your Free Trial

Biosyent's Enterprise Value for the quarter that ended in Dec. 2023 was C$83.29 Mil. Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$8.60 Mil. Biosyent's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 10.33%.

The historical rank and industry rank for Biosyent's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

TSXV:RX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.83   Med: 7.3   Max: 21.72
Current: 11.75

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Biosyent was 21.72%. The lowest was 1.83%. And the median was 7.30%.

TSXV:RX's Earnings Yield (Joel Greenblatt) % is ranked better than
88.38% of 1093 companies
in the Drug Manufacturers industry
Industry Median: 2.54 vs TSXV:RX: 11.75

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biosyent's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 14.50%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Biosyent Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Biosyent's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.46 6.88 10.99 13.09 10.33

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.09 10.56 11.71 13.04 10.33

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent Earnings Yield (Joel Greenblatt) % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Biosyent's Earnings Yield (Joel Greenblatt) % falls into.



Biosyent Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Biosyents Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=8.602/83.286942
=10.33 %

Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$8.60 Mil.



Biosyent  (TSXV:RX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Biosyent Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Biosyent's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (TSXV:RX) Business Description

Industry
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (TSXV:RX) Headlines

No Headlines